Savi Telmisartan 80 medicine for hypertension (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Telmisartan

Ingredient

Thành phần cho 1 viên

Composition information	Content
Telmisartan	80mg

Uses

Indication

Savi Telmisartan 80 is indicated in the following cases:

Treatment of hypertension: Can be used alone or in combination with other anti -blood pressure drugs .

Telmisartan is a specific antagonist of Angiotensin II receptor (Type AT1) in smooth and adrenal smooth muscles.

Pharmacokinetics

absorption

Telmisartan is rapidly absorbed through the gastrointestinal tract. Absolute oral bioavailability depends on the dose: about 42% after taking the dose of 40 mg and 58% after or taking the dose of 160 mg. The presence of eating mitigates Telmisartan bioavailability (decreases about 6% when using a dose of 40 mg). After drinking, the highest drug concentration in plasma is achieved after 0.5 - 1 hour.

Distribution

Mount with plasma proteins more than 99%, mainly on albumin and α1 - Glycoprotein acid. The distribution volume is about 500L.

Metabolism

Telmisartan is metabolized by combining with glucuronid of the original compound into non -active substance.

Elimination

After oral use, Telmisartan is almost except for feces, mainly in the form of unchanged compounds. Excretion accumulated through urine is less than 1% of the dose. Total clearance in plasma (about 1,000 ml/min) compared to the blood flow through the liver (about 1500 ml/min).

Before taking Savi Telmisartan 80 medicine for hypertension (3 blisters x 10 tablets)

How to use

Savi Telmisartan is taken orally.

Dosage

Adults

Take 40 mg/1 time/day. For some patients, only a dose of 20 mg/1 time/day. If necessary, may increase to a maximum dose of 80 mg/time/day. Telmisartan can be combined with thiazid diuretics. Before increasing the dose, it should be noted that the maximum anti -hypertension effect is achieved between the 4th and 8th weeks from the beginning of treatment.

kidney failure

For patients with severe kidney failure or dialysis, the recommended starting dose is 20 mg/day. No need to adjust the dose in patients with mild and medium renal failure.

Hepatic failure

If mild or moderate liver failure, daily dose must not exceed 40 mg/daily.

Elderly

No dose adjustment.

Children under 18 years old

Safety and efficiency have not been determined.

The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when overdose? In addition, slow heart rate, dizziness, increased serum creatinine and acute renal failure are also reported. Hematoparoa does not remove Telmisartan. Patients should be closely monitored and treated symptoms and support. The method of handling poisoning depends on the time from taking the drug and the severity of the symptoms. Can cause vomiting or gastric lavage. Activated carbon shows beneficial in this case. Regular monitoring of electrolytes and serum creatinine. If hypotension occurs, the patient should be placed on his back and quickly compensate for salt and water.

What to do when you forget a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Note that it should not be used double the prescribed dose.

Side Effects

When using the drug, you may experience unwanted effects (ADR).

Uncommon, 1/1000

Body: Fatigue, headache , dizziness, limb edema, sweating.

Central nervous system: agitation. digestion: dry mouth, nausea, abdominal pain, acid reflux, indigestion, flatulence, anorexia, diarrhea .

urinary tract: Reducing kidney function, increased creatinine and nitrogen urea (bun), urinary tract infections. Respiratory: sore throat , sinusitis, upper respiratory tract infections (cough, congestion or ear pain, fever, nasal congestion, runny nose, sneezing, sore throat).

bone - joints: back pain, pain and muscle spasm.

Metabolism: hyperkalemia.

Rare, ADR

Systemic: Evaluation.

Eye: visual disorders.

Cardiovascular: tachycardia, reducing blood pressure or fainting (common in people with blood volume reduced or reduced salt, treatment with diuretics, especially in standing posture).

Instructions on how to handle ADR

Treatment of symptomatic hypotension: Put the patient on your back, if it is necessary to inferalize the physiological saline solution.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Too hypersensitivity to Telmisartan.

Too hypersensitivity to any ingredients of the drug.

Pregnant women.

Women who are breastfeeding.

Severe liver failure. biliary clogged.

Severe kidney failure. Renal failure has a concentration of blood creatinine ≥ 250 micromol/liter or potassium ≥ 5 mmol/liter or Clcr

diabetes or renal function impairment (GFR

Caution when used

must not be used for patients with bile stasis, bile congestion disorders or severe liver failure because Telmisartan is eliminated by bile. These patients may be reduced in the liver for Telmisartan. Should only be used carefully for patients with mild to moderate liver failure.

Increased risk of severe hypotension and renal failure when patients with narrowed kidney stenosis or artery stenosis to a single active kidney are treated with drug products that affect the Renin - Angiotensin - Aldosterone system.

When used for patients with impaired renal function, periodic monitoring of potassium and serum creatinine should be monitored. There is no experience in using patients with recent kidney transplants.

Symptomic hypotension, especially after the first dose, can occur in patients with decreased volume and / or sodium due to strong diuretic treatment, limiting salt in diet, diarrhea or vomiting. Such conditions should be repaired before use. The decline in volume and/or sodium should be adjusted before use.

There is evidence that the use of enzyme inhibitors simultaneously, Angiotensin II or Aliskiren receptor blockers increases the risk of hypotension, hyperkalemia and reducing kidney function (including acute renal failure). Therefore, it is not recommended that the RAAS system is at the same time by using the combination of enzyme inhibitors, Angiotensin II or Aliskiren receptor blockers.

Angiotensin II receptor inhibitors should not be used simultaneously for patients with diabetes due to diabetes.

In patients with vascular tone and renal function depends mainly on the activity of the Renin - Angiotensin - Aldosterone system (for example, patients with severe congestive heart failure or potential renal disease, including kidney stenosis), treated with drug products that affect this system such as Telmisartan related to acute hypotension, hyperburgery, rarity.

Patients with primary aldosteron increases in general will not respond to antihypertensive drugs that inhibit the Renin - Angiotensin system. Therefore, the use of Telmisartan is not recommended.

As well as other vasodilators, especially cautious in patients with aortic valve stenosis or mitral valve, or obstructive hypertrophic cardiomyopathy.

In these patients, hypoglycemia can occur when treated with Telmisartan. Therefore, in these patients, it is necessary to consider and monitor appropriate blood sugar; Insulin or anti -diabetes may be required, when indicated.

The use of drug products that affect the Renin - Angiotensin - Aldosterone system can cause hypokalemia.

In the elderly, in patients with renal impairment, in patients with diabetes, in patients treated simultaneously with other drug products may increase potassium levels and/or in patients with simultaneous events, hyperkalemia can be fatal.

Telmisartan and other Angiotensin II receptor antagonists seem to be less effective in hypotension in blacks than black people.

As with any lowering hypotension, excessive reducing blood pressure in patients with myocardial ischemia or cardiovascular disease due to ischemia can lead to myocardial infarction or stroke.

The ability to drive and operate machinery

Tell patients to be cautious when driving, using machinery or doing other things can be dangerous, because it may be dizzy, dizzy due to lower blood pressure.

Pregnancy

due to caution, Telmisartan should not be used in the first 3 months of pregnancy. If you intend to get pregnant, other drugs should be replaced before pregnancy. Contraindicated Telmisartan from the 3rd month of pregnancy. When detecting pregnancy, Telmisartan must be stopped as soon as possible.

Breastfeeding period

Contraindications to use Telmisartan during breastfeeding because it is not known whether Telmisartan will excrete in breast milk or not. Must decide to stop breastfeeding or stop the drug, depending on the importance of the drug for the mother.

Medicinal interaction

Digoxin: simultaneously used with Telmisartan increases the peak concentration (49%) and the bottom concentration (20%) of digoxin. Need to adjust the dose of digoxin when using copper with telmisartan.

Similar to drugs that affect the reninangiotensin system - Aldosterol, Telmisartan may increase potassium. The higher the risk of hyperkalemia when used in combination with other drugs also increases potassium (potassium salts, potassium -saving dtered pills, ACE inhibitors, Angiotensin II receptor anti -receptor, nonsteroidal anti -inflammatory drugs, heparin, immunosuppressant drugs such as cyclosporin or tacrolimus , and trimethoprim).

Potassium -saving diocesia or potassium supplements: Angiotensin II antagonistic drugs reduce potassium excretion; When used with potassium -saving pepper (Spironolacton, Eplerenon, triamteren , amilorid) or potassium supplements can increase potassium. So if shared, need to be cautious and regularly monitor the agricultural potassium.

Lithi: Telmisartan may increase the concentration and toxicity of lithium when used simultaneously. If used simultaneously, regular monitoring of blood lithium concentration.

Non-Steroid anti-inflammatory drugs (NSAID: Nonsteroidal Anti-inflation Drug): NSAID can reduce the effect of Hydroption of Angiotensin II receptor antagonists. In patients with impaired renal function, this combination worsen kidney disease, which can cause acute renal failure. Therefore, be careful when using NSAID and Telmisartan.

Diuretics using high -dose diuretics (Furosemid, hydrochlorothiazide ) can reduce fluid volume and have a risk of hypotension when starting with Telmisartan.

corticoid: reduces the hypotension effect of telmisartan.

Other hypotension drugs: simultaneously use many drugs that affect the Renin - Angiotensin - Aldosteron system (ACE inhibitors, Angiotensin II or Aliskiren antagonists) that are more frequent than unwanted effects such as hypotension, hyperboly, impaired renal function. Baclofen and amifostin drugs may increase the hypotension effect of Telmisartan. In addition, alcohol, sedative and sleeping pills can worsen the unwanted effect of Telmisartan's standing blood pressure.

wafarin: Concomitance with Telmisartan for 10 days reduces blood wafarin levels but does not change Inr.

Storage

Leave a cool place, avoid light, temperature below 30⁰C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.